Investing.com - Oramed reported on Wednesday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Oramed announced earnings per share of $-0.27 on revenue of $674.0K. Analysts polled by Investing.com anticipated EPS of $-0.24 on revenue of $700K.
Oramed shares are down 35.99% from the beginning of the year, still down 71.02% from its 52 week high of $31.54 set on November 3, 2021. They are under-performing the Nasdaq which is down 18.79% from the start of the year.
Oramed follows other major Healthcare sector earnings this month
Oramed's report follows an earnings missed by Eli Lilly on August 4, who reported EPS of $1.25 on revenue of $6.49B, compared to forecasts EPS of $1.7 on revenue of $6.85B.
Pfizer had beat expectations on July 28 with second quarter EPS of $2.04 on revenue of $27.74B, compared to forecast for EPS of $1.72 on revenue of $25.49B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar